H01 Significant biological and clinical change detected over 1 year in premanifest and early stage Huntington's disease in the TRACK-HD study

Tabrizi, S J; Dürr, A; Roos, R A C; Leavitt, B R; Jones, R; Landwehrmeyer, G B; Johnson, H; Hicks, S L; Kennard, C; Reilmann, R; Craufurd, D; Rosas, H D; Frost, C; Langbehn, D R; Scahill, R I; Stout, J C
September 2010
Journal of Neurology, Neurosurgery & Psychiatry;Sep2010 Supp, Vol. 81, pA33
Academic Journal
Background/aims TRACK-HD is a multinational prospective, observational study of Huntington's disease (HD) that aims to examine longitudinal change in premanifest carriers of the mutant HTT gene and subjects with early stage disease (Tabrizi 2009). New data from the first follow-up assessment are reported here, and build on previous findings from baseline 3T MRI and novel clinical, cognitive, quantitative motor, oculomotor and neuropsychiatric assessments. Of 366 subjects enrolled at baseline, 345 (115 controls, 116 premanifest (preHD) and 114 early HD) completed 12 months of follow-up. Statistical analysis was performed to assess annualised change in all modalities. Methods/techniques Annualised rates of global and regional atrophy were higher in both the pre- and early HD groups than in controls (p≤0.007). Whole brain atrophy rates were 0.3%, 0.5% and 0.9%, and caudate atrophy rates 0.6%, 2.0% and 3.5%, in controls, pre and early HD, respectively, over 1 year. Whole brain image analysis techniques also revealed striking cortical and subcortical grey and white matter atrophy over just 1 year even in subjects furthest from predicted disease onset. Quantitative imaging showed significant associations with disease burden and total functional capacity, a widely used clinical measure of disease severity. Cognitive deterioration was detectable in both HD groups. However, rates of decline in cognitive, quantitative motor and oculomotor tasks were greater after onset of motor signs. Results/outcome HD is characterised by a long premanifest state, slow progression and a disease course of around 20 years. After 1 year, we have identified robust change in a range of measures across modalities in both premanifest and early stage HD. Quantitative imaging showed the greatest differentiation across the spectrum of the disease and a number of functional measures of decline were sensitive in early HD with cognitive impairment also detectable in the pre-HD group. Conclusions TRACK-HD is the first multi-site study to report whole brain, regional and subcortical atrophy in premanifest subjects many years from predicted disease onset using 3T MR imaging; and demonstrates the feasibility of obtaining quantifiable endpoints which show robust change over just 1 year thus showing potential as endpoints for future therapeutic trials.


Related Articles

  • F14 Speeded tapping assesses progression of huntington's disease within one year—results from the track-HD study. Bechtel, N; Acharya, T; Sturrock, A; Jauffret, C; Say, M J; Patel, A; Read, J E; t'Hart, E; van den Bogaard, S J A; Dürr, A; Leavitt, B R; Roos, R A C; Langbehn, D R; Tabrizi, S J; Reilmann, R // Journal of Neurology, Neurosurgery & Psychiatry;Sep2010 Supp, Vol. 81, pA27 

    Background Speeded (ST) and metronome (MT) tapping have been shown to be sensitive in distinguishing premanifest (preHD) and manifest (HD) stages of Huntington's disease (HD) in the cross-sectional analysis of the TRACK-HD study, and to detect an early motor phenotype even more than 14 years...

  • Early atrophy of pallidum and accumbens nucleus in Huntington's disease. van den Bogaard, Simon J. A.; Dumas, Eve M.; Acharya, Tanka P.; Johnson, Hans; Langbehn, Douglas R.; Scahill, Rachael I.; Tabrizi, Sarah J.; van Buchem, Mark A.; van der Grond, Jeroen; Roos, Raymund A. C. // Journal of Neurology;Mar2011, Vol. 258 Issue 3, p412 

    In Huntington's disease (HD) atrophy of the caudate nucleus and putamen has been described many years before clinical manifestation. Volume changes of the pallidum, thalamus, brainstem, accumbens nucleus, hippocampus, and amygdala are less well investigated, or reported with contradicting...

  • POMD07 Quantitative assessment of biological and clinical manifestations of Huntington's disease before and after diagnosis—the TRACK-HD study. N Lahiri // Journal of Neurology, Neurosurgery & Psychiatry;Nov2010, Vol. 81 Issue 11, pe59 

    BACKGROUND: Huntington's disease (HD) is a fully penetrant dominantly inherited neurodegenerative disease. The aim of this study was to identify sensitive and reliable biomarkers in clinically premanifest HD gene carriers and early HD patients. METHODS: TRACK-HD is a multinational longitudinal...

  • I02 Automated longitudinal measures of global and regional brain volume change in premanifest and early Huntington's disease. Gibbard, C; Scahill, R I; Malone, I; Dürr, A; Leavitt, B R; Roos, R A C; Tabrizi, S J; Hobbs, N // Journal of Neurology, Neurosurgery & Psychiatry;Sep2010 Supp, Vol. 81, pA36 

    Background TRACK-HD is an international multi-site study of premanifest and early Huntington's disease (HD) which aims to investigate a range of biomarkers for use in future therapeutic trials. Detecting subtle brain changes in slowly progressive heterogeneous diseases such as HD is a challenge....

  • Altered brain mechanisms of emotion processing in pre-manifest Huntington's disease. Novak, Marianne J. U.; Warren, Jason D.; Henley, Susie M. D.; Draganski, Bogdan; Frackowiak, Richard S.; Tabrizi, Sarah J. // Brain: A Journal of Neurology;Apr2012, Vol. 135 Issue 4, p1165 

    Huntington's disease is an inherited neurodegenerative disease that causes motor, cognitive and psychiatric impairment, including an early decline in ability to recognize emotional states in others. The pathophysiology underlying the earliest manifestations of the disease is not fully...

  • Reliability and Minimal Detectable Change of Physical Performance Measures in Individuals With Pre-manifest and Manifest Huntington Disease. Quinn, Lori; Khalil, Hanan; Dawes, Helen; Fritz, Nora E.; Kegelmeyer, Deb; Kloos, Anne D.; Gillard, Jonathan W.; Busse, Monica // Physical Therapy;Jul2013, Vol. 93 Issue 7, p942 

    Background. Clinical intervention trials in people with Huntington disease (HD) have been limited by a lack of reliable and appropriate outcome measures. Objective. The purpose of this study was to determine the reliability and minimal detectable change (MDC) of various outcome measures that are...

  • F24 Differences in companion and subject ratings of subjects' behaviour using the frontal systems behaviour scale (FrSBe)- findings from the track-hd study. Callaghan, J; Craufurd, D; Acharya, T; Dürr, A; Leavitt, B R; Roos, R A C; Langbehn, D R; Stout, J C; Tabrizi, S J // Journal of Neurology, Neurosurgery & Psychiatry;Sep2010 Supp, Vol. 81, pA30 

    Background TRACK-HD is a multi-centre, longitudinal study investigating a range of motor, cognitive, neuropsychiatric and imaging measures as potential biomarkers for clinical trials in Huntington's disease (HD). The neuropsychiatric battery includes the Frontal Systems Behaviour Scale (FrSBe),...

  • F04 Quality of life in Huntington's disease: a comparative study investigating the impact on spouses of those with premanifest and early disease. Read, J E; A, T P; Langbehn, D R; Owen, G; Dürr, A; Leavitt, B R; Roos, R A C; Stout, J C; Tabrizi, S J; Craufurd, D // Journal of Neurology, Neurosurgery & Psychiatry;Sep2010 Supp, Vol. 81, pA23 

    Background Huntington's disease (HD) is a progressive, inherited neurodegenerative condition, with onset usually in mid-life, affecting motor, cognitive and neuropsychiatric functions. Not surprisingly, studies have suggested that HD has a detrimental effect on the quality of life (QoL) of...

  • Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. Stout, Julie C.; Jones, Rebecca; Labuschagne, Izelle; O'Regan, Alison M.; Say, Miranda J.; Dumas, Eve M.; Queller, Sarah; Justo, Damian; Dar Santos, Rachelle; Coleman, Allison; Hart, Ellen P.; Dürr, Alexandra; Leavitt, Blair R.; Roos, Raymund A.; Langbehn, Doug R.; Tabrizi, Sarah J.; Frost, Chris // Journal of Neurology, Neurosurgery & Psychiatry;Jul2012, Vol. 83 Issue 7, p687 

    Background Deterioration of cognitive functioning is a debilitating symptom in many neurodegenerative diseases, such as Huntington's disease (HD). To date, there are no effective treatments for the cognitive problems associated with HD. Cognitive assessment outcomes will have a central role in...


Read the Article


Sign out of this library

Other Topics